Rapid progression of neurotoxoplasmosis in a patient with concomitant rheumatoid arthritis and systemic lupus erythematous

Matheus Fernandes de Oliveira Cristiana Borges Pereira Vitor Brito SilvaI Maristela Carvalho Costa Vitor Ribeiro Paes Roberto El Ibrahim About the authors

Dear Editor

Toxoplasmosis is one of the most common human infections. About one-third of the entire world population is infected with latent toxoplasmosis.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...

5 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10.
-66 Pulivarthi S, Reshi RA, McGary CT, Gurram MK. Cerebral toxoplasmosis in a patient on methotrexate and infliximab for rheumatoid arthritis. Intern Med. 2015;54(11):1433-6. DOI:10.2169/internalmedicine.54.397
https://doi.org/10.2169/internalmedicine...
Central nervous system (CNS) toxoplasmosis occurs due to reactivation of previous latent infection. Patients usually present with fever, headache, impaired consciousness, seizures, and/or focal neurological deficits.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
-55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10.

CNS toxoplasmosis may complicate the clinical course of patients with acquired human immunodeficiency (e.g. AIDS), immune system disease, or prolonged pharmacologic immunosuppressive treatment.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
-55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10. Because the clinical picture and diagnosis are challenging, neurotoxoplasmosis may mimic several other CNS disorders, being especially difficult to manage and frequently requiring empiric treatment.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
-55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10.

We present an unusual case of neurotoxoplasmosis developing in a patient with concomitant rheumatoid arthritis and systemic lupus erythematous (SLE).

CASE DESCRIPTION

History. A 60-year-old female patient complaining of progressive holocranial headache for 60 days, worsening two days before admission to hospital. Additionally she reported daily nausea and vomiting. Fever was absent. Her physical examination revealed a central facial paresis at left and typical articular deformities in feet, hands and knees, suggestive of rheumatoid arthritis.

She had been treated for rheumatoid arthritis and systemic lupus erythematous for 37 years: currently, she was in use of Prednisone 5mg/day; Levotiroxine 50mcg/day; aspirin 100mg/day and sertraline 50mg/day. She discontinued some of the medications 2 weeks before admission to Hospital, maintaining only levothyroxine and sertraline.

She had already used chloroquine, methotrexate and leflunomide years before. She discontinued use of chloroquine due to corneal abrasion; methotrexate and leflunomide were discontinued due to digestive symptoms five years before.

Imaging results. Computerized tomography and magnetic resonance revealed multiple nodular images of different sizes in the supratentorial cortex, especially in the cortico-subcortical interface, with vasogenic edema. There was contrast enhancement in the lesions: initially this was peripheral, but became homogeneous in a late phase (Figure 1). Angiographic images obtained through MR were normal, without signs of vasculitis in the entire intracranial arterial circulation. No signs of sinus thrombosis. Perfusional evaluation revealed increased blood flow and capillary permeability in all lesions. Spectroscopy displayed increased choline peak, decreased n-acetyl-aspartate (NAA) peak, as well as an increase in the lipid/lactate peak.

Figure 1
Magnetic resonance (MR) and computed tomography (CT) images displaying multiple cortical and subcortical parenchymal lesions, with enhancement after contrast infusion. Although it is a typical radiological presentation for neurotoxoplasmosis, it is also not specific.

To rule out other putative causes, the patient was submitted to abdominal and thoracic CT, both resulting normal. Breast and thyroid ultrassonographic evaluations were also normal. Endoscopic investigation was eventless. Cerebrospinal fluid analysis was fairly typical for viral meningitis: 62 cells (71% lymphocytes; 10% macrophages; 3% neutrophils; 16% monocytes), protein 410 mg/dL and glucose 174 mg/dL. Laboratorial tests were normal. C-reactive protein (2.07 mg/L) and hemosedimentation velocity (6 mm/h) were normal. Investigation for proteins C and S, antithrombin III, lupic anticoagulant were negative. Serologic tests were negative for HIV, Hepatitis B and C.

At this point an open brain biopsy was proposed. Surgery was uneventful.

Pathology. Macroscopic pathological examination revealed cerebral parenchyma with a perivascular lymphocytic pattern and reparative gliosis. There were marked suppurative areas, in which Toxoplasma gondii tachyzoites were identified. Immunohistochemistry revealed positivity to Toxoplasma gondii antibodies (Figure 2). No signs of granulomas or neoplasms were found.

Figure 2
Histology image in hematoxilin-eosin. From A to D, different degrees of image magnification. It is possible to see the lymphocytic cells surrounding areas of suppurative presentation containing tachyzoites (arrows).

Post-operative. In the second post-operative day the patient had impaired consciousness and developed acute respiratory failure, requiring intubation and ventilatory support. She progressively deteriorated, developed pneumonia and had severe sepsis, with multiple organ dysfunction. We introduced pyrimethamine and sulfadiazine but at the seventh post-operative day, in spite of all of the adopted measures, her pupils became middle sized and fixed, with no brainstem reflexes and she died due to refractory intracranial hypertension.

DISCUSSION

Table 1 summarizes similar cases previously reported. Here we report an unusual presentation of neurotoxoplasmosis in a middle aged white woman harboring both rheumatoid arthritis and SLE. Although her previous medical history showed use of immunosupressors (leflunomide, methotrexate and prednisone), she developed a rapid progression of CNS neuroinfection without current immunosuppression therapy.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
-55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10. We believe that surgical procedure did not change clinical course of disease however was important to identify etiological agent.

Table 1
Data of published cases of cerebral toxoplasmosis after imunosupression drugs.

Toxoplasma gondii infection is a common disease worldwide. Acute infection in an immunocompetent host is usually asymptomatic. In immunodeficient patients, cerebral toxoplasmosis may develop with 3 major pathologic patterns, which are diffuse encephalopathy with or without seizures, meningoencephalitis, and singular or large progressive mass lesions. Definitive diagnosis may require the presence of Toxoplasma antibodies in serum. In some doubtful cases, brain biopsy can provide a definitive diagnosis.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
-55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10.

A relationship between rheumatoid arthritis and SLE with opportunistic infections, including toxoplasmosis in its cerebral form has been reported.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
-55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10. Nardone et al.22 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...
reported the development of cerebral toxoplasmosis in a patient under treatment with adalimumab for rheumatoid arthritis. Lassoued et al.33 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...
documented two cases of toxoplasmic chorioretinitis following anti-TNF alpha treatment (with adalimumab, infliximab and etanercept) for rheumatoid arthritis. Cerebral toxoplasmosis associated with immunosuppressive medication has been reported by Safa et al.44 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
and Nakamura et al.55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10.

Young et al11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...
reported a case of cerebral toxoplasmosis in a patient receiving multiple immunosuppressive medications, including methotrexate, infliximab, prednisone and leflunomide for rheumatoid arthritis11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...
. Pulivarthi et al.66 Pulivarthi S, Reshi RA, McGary CT, Gurram MK. Cerebral toxoplasmosis in a patient on methotrexate and infliximab for rheumatoid arthritis. Intern Med. 2015;54(11):1433-6. DOI:10.2169/internalmedicine.54.397
https://doi.org/10.2169/internalmedicine...
described a case of 76 year old woman with methotrexate and infliximab. Pistacchi et al77 Pistacchi M, Gioulis M, Zirillo M, Francavilla E, Zambito Marsala S. Cerebral toxoplasmosis in undifferentiated connective disease treated with mycophenolate mofetil: an unusual case report. Acta Neurol Belg. 2016;116(4):633-6. DOI:10.1007/s13760-015-0595-9
https://doi.org/10.1007/s13760-015-0595-...
described a case of 48 year old woman with Mycophenolate Mofetil. Pagalavan et al88 Pagalavan L, Kan FK. Cerebral toxoplasmosis in systemic lupus erythematosus following intravenous methylprednisolone. Med J Malaysia. 2011;66(1):68-70. reported a case of a 18 year old woman after intravenous methylprednisolone.

Thus, all the authors here presented propose that cerebral toxoplasmosis should be considered in the differential diagnosis of patients receiving immunosuppressive medications, such as methotrexate, rituximab, adalimumab and infliximab, who present with neurological manifestations.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
-55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10.

Although scarcely represented in literature in the form of case reports, it seems clear that there is a potential risk of toxoplasmosis activation in patients requiring immunosuppression treatments in the context of rheumatoid arthritis and SLE, either in acute or in chronic presentation.11 Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
https://doi.org/10.1056/NEJMc051556...

2 Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
https://doi.org/10.1093/rheumatology/ket...

3 Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
https://doi.org/10.1016/j.semarthrit.200...

4 Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
https://doi.org/10.1001/jamainternmed.20...
-55 Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10. Such patients should be screened for toxoplasmosis before starting medication and should also be screened in routine control evaluations. Moreover, due to its severity and potential lethal evolution, neurotoxoplasmosis should be empirically treated in the presence of unexpected neurological symptoms in such patients, while other causes are simultaneously investigated. Knowledge of the patient's seropositive status helps close monitoring and the ability to provide early treatment, if necessary.

REFERENCES

  • 1
    Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005;353(14):1530-1; discussion 1530-1. DOI:10.1056/NEJMc051556
    » https://doi.org/10.1056/NEJMc051556
  • 2
    Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(2):284. 10.1093/rheumatology/ket364
    » https://doi.org/10.1093/rheumatology/ket364
  • 3
    Lassoued S, Zabraniecki L, Marin F, Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2007;36(4):262-3. DOI:10.1016/j.semarthrit.2006.08.004
    » https://doi.org/10.1016/j.semarthrit.2006.08.004
  • 4
    Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med. 2013 May 27;173(10):924-6. DOI:10.1001/jamainternmed.2013.374
    » https://doi.org/10.1001/jamainternmed.2013.374
  • 5
    Nakamura M, Nagai M, Shiga Y, Aoki M, Abe T, Kaku M, et al. [Toxoplasma encephalitis in a patient receiving cyclosporine monotherapy for Behçet disease]. Rinsho Shinkeigaku. 2005;45(2):105-10.
  • 6
    Pulivarthi S, Reshi RA, McGary CT, Gurram MK. Cerebral toxoplasmosis in a patient on methotrexate and infliximab for rheumatoid arthritis. Intern Med. 2015;54(11):1433-6. DOI:10.2169/internalmedicine.54.397
    » https://doi.org/10.2169/internalmedicine.54.397
  • 7
    Pistacchi M, Gioulis M, Zirillo M, Francavilla E, Zambito Marsala S. Cerebral toxoplasmosis in undifferentiated connective disease treated with mycophenolate mofetil: an unusual case report. Acta Neurol Belg. 2016;116(4):633-6. DOI:10.1007/s13760-015-0595-9
    » https://doi.org/10.1007/s13760-015-0595-9
  • 8
    Pagalavan L, Kan FK. Cerebral toxoplasmosis in systemic lupus erythematosus following intravenous methylprednisolone. Med J Malaysia. 2011;66(1):68-70.

Publication Dates

  • Publication in this collection
    2018

History

  • Received
    21 Dec 2017
  • Reviewed
    30 Jan 2018
  • Accepted
    25 Feb 2018
Mavera Edições Técnicas e Científicas Ltda Rua Professor Filadelfo Azevedo, 220, Cep: 04508-010, tel: (11) 3051 3043 - São Paulo - SP - Brazil
E-mail: medicalexpress@me.net.br